文献速递支持与姑息治疗

神经内分泌肿瘤患者COVID-19特征:INTENSIVE研究初步结果

Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study.
PubMed 文献 · Eur J Cancer · 2021-06-30

INTENSIVE研究全球收集2020年6月至2021年3月SARS-CoV-2阳性神经内分泌肿瘤患者89例,中位年龄64岁,多为转移性、无功能、低/中级别胃肠胰NEN,接受生长抑素类似物和放射配体治疗。多数有合并症,仅8%高级别、12%化疗。超过80%完全康复无后遗症,7.8%死于COVID-19。

要点

  • NEN患者COVID-19多无需重症监护,短期无后遗症。
  • 多数抗NEN治疗未因COVID-19中断。
  • 7.8%患者死于COVID-19。

核心结论

  • 纳入患者反映典型NEN人群,多数无需重症监护即康复,短期无后遗症且未中断全身抗肿瘤治疗。

研究设计与样本

  • 全球性研究,直接联系81个NEN治疗中心,收集2020年6月1日至2021年3月31日SARS-CoV-2 RT-PCR阳性NEN患者,排除小细胞肺癌和混合性腺神经内分泌癌。

主要发现

  • 截至2021年3月31日,8个招募中心入组89例患者,中位年龄64岁。
  • 多数患者为转移性、无功能、低/中级别胃肠胰NEN,接受生长抑素类似物和放射配体治疗,且多数有合并症。
  • 仅8%为高级别NEN,12%接受化疗;多数有COVID-19症状体征,主要为发热和咳嗽。
  • 仅3例接受亚重症治疗,多数接受药物治疗(主要为抗生素);三分之二病例抗NEN治疗无变化。
  • 超过80%完全康复无后遗症,7.8%死于COVID-19。

临床怎么用

  • NEN患者感染COVID-19时,多数可继续抗NEN治疗,无需重症监护。

局限性

  • 初步结果,样本量有限,仅8个中心入组89例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Specific data regarding coronavirus disease 2019 (COVID-19) in patients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive. MATERIAL AND METHODS: This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating patients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma. RESULTS: Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31st, 2021, eight recruiting centres enrolled 89 patients. The median age was 64 years at the time of COVID-19 diagnosis. Most patients had metastatic, non-functioning, low-/intermediate-grade gastroenteropancreatic NENs on treatment with somatostatin analogues and radioligand therapy. Most of them had comorbidities. Only 8% of patients had high-grade NENs and 12% were receiving chemotherapy. Most patients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients underwent sub-intensive treatment, whereas most of them received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae, whereas 7.8% patients died due to COVID-19. CONCLUSIONS: Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fazio N, Gervaso L, Halfdanarson TR, et al. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. Eur J Cancer. 2021. PMID: 34298375. doi:10.1016/j.ejca.2021.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。